Tofacitinib in Scleritis: A Case Series

Richa Pyare; Parthopratim Dutta Majumder; Mauli Shah; Viswanathan Kaushik; Mamta Agarwal; Jyotirmay Biswas

doi:10.1080/09273948.2022.2113805

Tofacitinib in Scleritis: A Case Series

Richa Pyare
, Parthopratim Dutta Majumder
, Mauli Shah
, Viswanathan Kaushik
, Mamta Agarwal
, Jyotirmay Biswas

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Purpose: To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used. Method: A retrospective chart review. Result: Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months. Conclusion: Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.

Original language	English (US)
Pages (from-to)	884-890
Number of pages	7
Journal	Ocular Immunology and Inflammation
Volume	32
Issue number	6
DOIs	https://doi.org/10.1080/09273948.2022.2113805
State	Published - 2024
Externally published	Yes

Keywords

JAK kinase inhibitor
necrotizing scleritis
nodular scleritis
scleritis
tofacitinib

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.1080/09273948.2022.2113805

Cite this

@article{934c534cd0094481994dbe6676bbd8b5,

title = "Tofacitinib in Scleritis: A Case Series",

abstract = "Purpose: To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used. Method: A retrospective chart review. Result: Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months. Conclusion: Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.",

keywords = "JAK kinase inhibitor, necrotizing scleritis, nodular scleritis, scleritis, tofacitinib",

author = "Richa Pyare and \{Dutta Majumder\}, Parthopratim and Mauli Shah and Viswanathan Kaushik and Mamta Agarwal and Jyotirmay Biswas",

note = "Publisher Copyright: {\textcopyright} 2022 Taylor \& Francis Group, LLC.",

year = "2024",

doi = "10.1080/09273948.2022.2113805",

language = "English (US)",

volume = "32",

pages = "884--890",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Tofacitinib in Scleritis

T2 - A Case Series

AU - Pyare, Richa

AU - Dutta Majumder, Parthopratim

AU - Shah, Mauli

AU - Kaushik, Viswanathan

AU - Agarwal, Mamta

AU - Biswas, Jyotirmay

PY - 2024

Y1 - 2024

N2 - Purpose: To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used. Method: A retrospective chart review. Result: Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months. Conclusion: Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.

AB - Purpose: To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used. Method: A retrospective chart review. Result: Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months. Conclusion: Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.

KW - JAK kinase inhibitor

KW - necrotizing scleritis

KW - nodular scleritis

KW - scleritis

KW - tofacitinib

UR - https://www.scopus.com/pages/publications/85138757517

UR - https://www.scopus.com/pages/publications/85138757517#tab=citedBy

U2 - 10.1080/09273948.2022.2113805

DO - 10.1080/09273948.2022.2113805

M3 - Article

C2 - 36126052

AN - SCOPUS:85138757517

SN - 0927-3948

VL - 32

SP - 884

EP - 890

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 6

ER -

Tofacitinib in Scleritis: A Case Series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this